Table 3 Hazard ratios for overall survival and recurrence free survival in pancreatobiliary type tumours

Age

0.99 (0.96-1.02)

1.02 (0.99-1.05)

0.98 (0.96-1.01)

0.99 (0.96-1.02)

Sex

Women

Men

1.24 (0.80-1.91)

1.02 (0.64-1.64)

1.09 (0.72-1.66)

0.82 (0.52-1.30)

Tumour size

1.03 (1.01-1.05)

1.01 (0.99-1.04)

1.04 (1.02-1.05)

1.01 (0.99-1.04)

Tumour grade

Well-moderate

Poor

2.50 (1.54-4.05)

2.10 (1.28-3.45)

2.40 (1.50-3.83)

2.35 (1.43-3.84)

Tumour origin

Ampulla

Distal bile duct

0.74 (0.40-1.34)

1.02 (0.53-1.98)

1.10 (0.61-1.97)

2.68 (0.33-21.81)

Pancreas

0.88 (0.49-1.60)

1.08 (0.56-2.08)

1.01 (0.56-1.84)

2.26 (0.27-18.81)

T-stage

T1

T2

1.93 (0.23-16,04)

0.54 (0.06-5.05)

2.21 (0.27-18.38)

0.61 (0.06-5.75)

T3

3.99 (0.55-28.85)

0.74 (0.09-6.10)

6.43 (0.89-46.43)

1.28 (0.16-10.29)

T4

5.11 (0.67-38.79)

2.36 (0.11-49.41)

5.95 (0.78-45.43)

0.93 (0.11-8.00)

N-stage

N0

N1

2.55 (1.49-4.38)

2.49 (1.42-4.38)

2.59 (1.55-4.33)

2.15 (1.22-3.80)

Margin status

R0

R1-Rx

4.02 (0.99-16.38)

2.43 (0.59-10.02)

2.71 (0.99-7.44)

2.30 (0.82-6.50)

Perineural

Pn0

Pn1

1.97 (1.10-3.53)

1.04 (0.50-2.15)

3.09 (1.66-5.75)

1.80 (0.94-3.46)

Lymphatic vessels

L0

L1

1.57 (0.96-2.56)

1.02 (0.57-1.85)

1.85 (1.14-3.01)

1.14 (0.65-2.00)

Blood vessels

V0

V1

2.43 (1.56-3.78)

2.53 (1.59-4.03)

2.35 (1.50-3.69)

1.96 (1.21-3.17)

Peripancreatic fat

Pn0

Pn1

1.89 (1.05-3.40)

0.94 (0.47-1.90)

2.75 (1.50-5.02)

1.78 (0.94-3.40)

SATB1

Negative

Positive

2.11 (1.25-3.56)

1.79 (1.05-3.05)

1.87 (1.10-3.18)

1.54 (0.89-2.66)

Adjuvant chemotherapy

None/other

Gemcitabine

0.76 (0.49-1.18)

0.56 (0.35-0.89)

0.98 (0.64-1.49)

0.72 (0.46-1.12)